IPN:EPA
Ipsen SA
€155.80
arrow_upward
+1.70%(+2.60) 1D
Nov 4, 5:35:03 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IPN...
Open
€154.50
High
€155.90
Low
€153.30
Mkt. cap
12.76B
Avg. vol.
115.00K
Volume
107.34K
P/E ratio
25.23
52-wk high
€174.00
52-wk low
€115.60
EPS
€6.18
Shares outstanding
83.81M
No. of employees
6K
Open
€154.50
High
€155.90
Low
€153.30
Mkt. cap
12.76B
Avg. vol.
115.00K
Volume
107.34K
P/E ratio
25.23
52-wk high
€174.00
52-wk low
€115.60
EPS
€6.18
Shares outstanding
83.81M
No. of employees
6K
News stories
From web sources and news partners
Yahoo Finance
·
41 minutes ago
Dow, S&P 500, Nasdaq Futures Mixed After A Democratic Sweep In Midterms: NVDA, MU, SNDK, NBIS, IREN In Focus
www.marketscreener.com
·
16 minutes ago
Backblaze Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mitrade
·
36 minutes ago
S&P 500 Flashes a Signal Never Seen in 36 Years. What’s Next?
Profile
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
About Ipsen SA
CEODavid Loew
Employees5.54K
Founded1929
Headquarters-
SectorPharmaceutical industry
Industry-
Websiteipsen.com